Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + oxaliplatin + 5-fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Fujian Medical University Cancer Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
POF is a triplet chemotherapy regimen consisting of paclitaxel, oxaliplatin, and 5-fluorouracil (5-FU) with leucovorin (calcium levofolinate), specifically investigated by Fujian Cancer Hospital for the treatment of advanced or metastatic gastric adenocarcinoma. The regimen functions through a multi-targeted approach: paclitaxel stabilizes microtubules to inhibit cell division, oxaliplatin induces DNA damage via cross-linking, and 5-fluorouracil inhibits thymidylate synthase to disrupt DNA synthesis, with leucovorin acting as a biochemical modulator to enhance the cytotoxic effect of 5-FU. In clinical studies at Fujian Cancer Hospital, the POF regimen has been evaluated as a first-line therapy, both as a standalone treatment and in combination with the VEGFR-2 tyrosine kinase inhibitor apatinib, demonstrating efficacy in improving outcomes for patients with advanced gastric malignancies.
- Other names
- POF regimenPaclitaxel-Oxaliplatin-Fluorouracil
02
Targets
TUBB (Tubulin (alpha and beta subunits))NeuraminidaseDNATS (Thymidylate synthase)
Beyond the preview
Go deeper on paclitaxel + oxaliplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + oxaliplatin + 5-fluorouracil + leucovorin.